A Message to the DGH Community - We are Here to Support You and We Stand with You

Dear DGH community,

We are reaching out in support and solidarity as we reel from recent events. Today, supporters of President Trump violently entered the US Capitol and disrupted the counting of certified electoral votes, encouraged by the President’s false claims of election fraud. The disruption of our democratic process in Washington, DC and the violence we are witnessing are deeply disturbing. We recognize that these scenes may be distressing, especially to members of our community who have lived through coups and civil unrest.

Opinion: Specialists Back Single-Dose Vaccine Strategy for COVID-19 (includes Ruanne Barnabas)

Even partial protection of one dose could be enough to slow the spread of the virus, the UW Medicine researchers argue in a paper.

MEDIA CONTACT: Susan Gregg - 206.616.6730, sghanson@uw.edu

Giving one dose of the COVID-19 vaccines currently approved in the United States could curtail the spread of the SARS-CoV-19 in the community more quickly than the recommended two doses, say two vaccine experts at the University of Washington School of Medicine.

UW Medicine starts Novavax COVID-19 vaccine clinical trial (includes Scott McClelland)

Volunteer enrollment begins for Phase III clinical trial that will determine the efficacy of Novavax vaccine candidate.

UW Medicine investigators are starting volunteer enrollment for an investigational COVID-19 vaccine clinical trial. The Phase III study will examine whether the Novavax vaccine candidate can protect against SARS-CoV-2, the coronavirus responsible for COVID-19.

How Safe and Effective Are the New Coronavirus Vaccines?

The U.S. Food and Drug Administration (FDA) has granted emergency use for two new coronavirus vaccines, one developed by the drug company Pfizer and the biotech company BioNTech and the other by the biotech company ModernaTX. Both are mRNA vaccines and have similar structure.

Both vaccines contain modified mRNA that provides the instructions for the synthesis of the SARS-CoV-2 spike glycoprotein antigen. Its mRNA is enveloped in lipid nanoparticles (LNPs) to prevent degradation and enhance uptake into cells.

Pages